[en] Abstract
Objective : To analyse the effect of differentiation on disease-free survival (DFS) and overall survival (OS) in patients with stage I adenocarcinoma of the endometrium. Patients and methods : From 1979 to 1995, 350 patients with FIGO stage IA–IC with well (G1), moderately (G2) or poorly (G3) differentiated tumors were treated with surgery and high dose-rate brachytherapy with or without external radiation. Median age was 65 years (39–86 years). Results : The 5-year DFS was 8863% for the G1 tumors, 7764% for the G2 tumors,
and 6767% for the G3 tumors (P50.0049). With regard to the events contributing to DFS, the 5-year cumulative percentage of local relapse was 4.6% for the G1 tumors, 9.0% for the G2 tumors, and 4.6% (P50.027) for the G3 tumors. Cumulative percentage of metastasis was 1.4, 6.3 and 7.2% (P,0.001), respectively, whereas percentages of death were 6.0, 7.9 and 20.7% (P,0.001). The 5-year OS was 9163, 8364 and 7667%, respectively (P50.0018). In terms of multivariate hazard ratios (HR), the relative differences between the three differentiation groups correspond to an increase of 77% of the risk of occurrence of either of the three events considered for the DFS (HR51.77, 95% Cl [0.94–3.33]), (P50.078) for the G2 tumors and of 163% (HR52.63, 95% Cl [1.27–5.43]), (P50.009) for the G3 tumors with respect to the G1 tumors. The estimated relative hazards for OS are, respectively, in line with those for DFS: HR51.51 (P50.282) for the G2 tumors; and HR53.37 (P50.003) for the G3 tumors. Conclusion : Patients with grade 1 tumors are those least exposed to either local relapse, metastasis, or death. In contrast patients with grade 2 tumors seem to be at higher risk of metastasis, whereas patients with grade 3 tumors appear at higher risk of death. Since we have looked at the first of three competing events (local relapse, metastasis and death), this suggests that patients with grade 3 tumors probably progress to death so fast that local relapse, if any, cannot be observed. Ó 2000 Elsevier Science Ireland Ltd. All rights reserved.
DiSaia P.J., Creasman W.T., Boronow R.C., Blessing J.A. Risk factors and recurrent patterns in stage I endometrial cancer. Am J Obstet Gynecol. 151:1985;1009-1015.
Mammoliti S., Bruzzone M., Chiara S., et al. Clinical stage I and II endometrial carcinoma: multivariate analysis of prognostic factors. Anticancer Res. 12:1992;1415-1418.
Creasman W.T., Boronow R.C., Morrow C.P., DiSaia P.J., Blessing J. Adenocarcinoma of the endometrium: its metastatic lymph node potential. Gynecol Oncol. 4:1976;239-243.
Price J.J. Vaginal involvement in endometrial carcinoma. Am J Obstet Gynecol. 91:1965;1060-1065.
Announcement. Changes in gynecologic cancer staging by the International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol 1990;162:610-11.
Aalders J., Abeler V., Kolstad P., Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Clinical and histopathologic study of 540 patients. Obstet Gynecol. 56:1980;419-426.
Ahmad N.R., Lanciano R., Corn B.W., Schultheiss T. Postoperative radiation therapy for surgically staged endometrial cancer: impact of time factor (overall treatment time and surgery-to-radiation interval) on outcome. Int J Radiat Oncol Biol Phys. 33:1995;837-842.
Rush S., Gal D., Potters L., Bosworth J., Lovecchio J. Pelvic control following external beam radiation for surgical stage I endometrial adenocarcinoma. Int J Radiat Oncol Biol Phys. 33:1995;851-854.
Stata. Computing Resource Center Reference Manual (1991).
Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
Greenwood M. Reports on public health and medical subjects: the natural duration of cancer. HMSO 1926;33:1-16.
Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., Mantel N., McPherson K., Peto J., Smith P.G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 35:1977;1-39.
Cox D.R. Regression models and life tables. J R Stat Soc B. 34:1972;187-220.
Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data. 1980;Wiley, New York.
Pepe M.S., Mori M., Kaplan-Meier E.L. Marginal or conditional probability curves in the analysis of competimg risk failure time data. Stat Med. 12:1993;737-751.
Piver M.S., Vongtama V. Parameters adversely affecting survival in women with stage I endometrial carcinoma. Am J Obstet Gynecol. 91:1965;1060-1065.
Malkasian G.D., Annegers J.F., Fountain K.S. Carcinoma of the endometrium: Stage I. Am J Obstet Gynecol. 136:1980;872-888.
Connelly P.J., Alberhasky R.C., Christopherson W.M. Carcinoma of the endometrium. III. Analysis of 865 cases with adenocarcinoma and adenoacanthoma. Obstet Gynecol. 59:1982;569-575.
Hendrickson M., Ross J., Eifel P., Cox R.S., Martinez A., Kempson R. Adenocarcinoma of the endometrium: analysis of 256 cases with carcinoma limited to the uterine corpus. Gynecol Oncol. 13:1982;373-392.
Boronow R.c., Morrow C.P., Creasman W.T., DiSaia P.J., Silverberg S.G., Miller A., Blessing J.A. Surgical staging in endometrial cancer. I. Clinical-pathologic findings of a prospective study. Obstet Gynecol. 63:1984;825-832.
Burke T.W., Heller P.B., Woodward J.E., Davidson S.A., Hoskins W.J., Park R.C. Treatment failure in endometrial carcinoma. Obstet Gynecol. 75:1990;96-101.
Morrow C.P., Bundy B.N., Kurman R.J., Creasman W.T., Heller P., Homesley H.D., Graham J.E. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group Study. Gynecol Oncol. 40:1991;55-65.
Christopherson W.M., Connelly P.J., Alberhasky R.C. Carcinoma of the endometrium: an analysis of prognosticators in patients with favorable subtypes and stage I disease. Cancer. 51:1983;1705-1709.
Vangtoma J., Kurohara S., Badihi A.O., Webster J.H. The value of adjuvant irradiation in the treatment of endometrial carcinoma Stage I, Group I. Cancer. 25:1970;45-49.
Joslin C.A., Vaishampayan G.V., Mallik A. The treatment of early cancer of the corpus uteri. Br J Radiol. 50:1977;38-45.
Reddy S., Lee M.S., Henderson F.R. Patterns of recurrences in endometrial carcinoma and their management. Radiol. 133:1979;737-740.
Aalders J., Abeler V., Kolstad P., Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma. Obstet Gynecol. 56:1980;419-426.
Marchetti L., Piver S., Tsukoda Y., Reese P. Prevention of vaginal recurrence of stage I endometrial adenocarcinoma with postoperative vaginal radiation. Obstet Gynecol. 67:1986;399-402.
Nori D., Hilaris B.S., Tome M., Lewis J.L. Jr., Birnbaum S., Fuks Z. Combined surgery and radiation in endometrial carcinoma: an analysis of prognostic factors. Int J Radiat Oncol Biol Phys. 13:1987;489-497.
Meerwaldt J.H., Hoekstra C.J.M., van Putten W.L.J., Subandono Tjokrowardojo A.J., Koper P.C.M. Endometrial adenocarcinoma adjuvant radiotherapy tailored to prognostic factors. Int J Radiat Oncol Biol Phys. 18:1990;299-304.
Sorbe B.G., Smeds A.C. Postoperative vaginal irradiation with high dose rate afterloading technique in endometrial carcinoma stage I. Int J Radiat Oncol Biol Phys. 18:1990;305-314.
Elliott P., Green D., Coates A., Krieger M., Russel P., Coppleson M., Solomon J., Tattersall M. The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer. Int J Gynecol Cancer. 4:1994;84-93.
Gibbons S., Martinez A., Schray M., Podratz K., Stanhope R., Garton G., Weiner S., Brabbins D., Malkasian G. Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int J Radiat Oncol Biol Phys. 21:1991;1019-1025.
